CRMD Stock Trading Plan: $8.50 Level and Price Targets
Explore the $CRMD stock trading plan, including the $8.50 must-hold level, price targets from $9.00 to $12.50, key catalysts, risks, and squeeze potential.
STOCK ANALYSIS
$CRMD Stock Analysis: Why It’s Trending, Full Detailed Trading Plan, and FAQ
Why CRMD Is Getting Investor Attention
Commercial Growth and Expanding Product Potential
CorMedix Inc. is gaining attention as its commercial business continues to scale around DefenCath, a product designed to help reduce catheter-related bloodstream infections in dialysis patients. During the second quarter of 2026, the company reported revenue of $101.9 million, adjusted EBITDA of $58.7 million, and earnings of $0.29 per diluted share. Management also reaffirmed full-year 2026 revenue guidance of $325 million to $345 million while raising adjusted EBITDA guidance to $125 million to $140 million.
Multiple Growth Drivers Ahead
The investment story extends beyond current DefenCath sales. CorMedix now has commercial supply agreements with all five of the largest U.S. dialysis providers, creating a potential path for broader adoption as new contracts and pilots develop. The company is also advancing Rezzayo as a potential treatment for preventing invasive fungal disease, with a supplemental FDA application expected during the third quarter of 2026. If accepted and approved, the expanded indication could give CorMedix another significant commercial opportunity and add a second major catalyst to the company’s growth story.
🚀 CRMD Trading Plan
🎯 Must-Hold Level: $8.50
The bullish setup remains valid only if CRMD holds $8.50 as support. An entry can be considered after the stock reclaims $8.50 and shows that buyers are defending the level, preferably with strong volume and a higher low. Avoid chasing a sharp move above the level without confirmation.
🛑 Risk Management
A decisive break below $8.50 invalidates the bullish setup. The stop-loss should be placed below the must-hold level according to your risk tolerance, allowing enough room to avoid being stopped by normal price volatility. If CRMD loses $8.50, do not continue holding based solely on the expectation that it will recover.
💰 Profit Targets
Target 1: $9.00
Take partial profits at $9.00, the first upside objective. If momentum weakens near this level, reduce additional exposure rather than expecting an immediate continuation.
Target 2: $9.85
If CRMD breaks above $9.00 and holds, the next profit target is $9.85. After reaching this level, consider raising the stop on the remaining position.
Target 3: $10.50
A sustained move through $9.85 would keep the bullish continuation pattern intact and place $10.50 in focus.
Target 4: $11.00
At $11.00, take another portion of the position off and protect profits on the remaining shares.
Target 5: $11.50
A clean break above $11.00 could create room for a move toward $11.50. Momentum and volume should remain strong for this target to stay active.
Target 6: $12.00
If buyers continue defending higher support levels, $12.00 becomes the next major profit-taking area.
Target 7: $12.50
The final extended target is $12.50. This target should be treated as a runner objective rather than a guarantee. Hold for it only while CRMD continues making higher highs, higher lows, and maintaining strong buying volume.
✅ Execution Rules
Bullish Scenario
- CRMD reclaims and holds $8.50.
- Buyers defend the level on a pullback.
- Volume expands as price moves through each resistance area.
- Take profits progressively at the seven targets.
- Raise the stop as the trade moves in your favor.
Bearish Invalidation
- CRMD loses $8.50 with strong selling pressure.
- The stock fails to reclaim the level after breaking below it.
- Volume expands on the breakdown.
- Exit according to the predetermined stop rather than holding and hoping.
Core plan: $8.50 is the line in the sand. Above it, manage the trade toward the profit targets; below it, the bullish setup is no longer valid.
❓ CRMD FAQ
🚀 What catalysts could push CRMD higher?
Key catalysts include continued DefenCath sales growth, broader adoption among dialysis providers, progress with the new commercial supply agreement, and the potential FDA review of Rezzayo for expanded use. Strong quarterly results, raised guidance, or positive clinical updates could also increase buying interest.
💊 Why is DefenCath important to CRMD?
DefenCath is the company’s primary commercial growth driver. Wider use across dialysis clinics, additional customer onboarding, Medicare Advantage agreements, and supporting real-world data could strengthen revenue visibility and improve investor confidence.
🧪 What is the Rezzayo catalyst?
CorMedix is pursuing an expanded indication for Rezzayo as a potential treatment to prevent invasive fungal disease. If the supplemental application is accepted and eventually approved, the expanded market opportunity could provide CRMD with another meaningful source of future growth.
📌 What price level must CRMD hold?
The key technical level is $8.50. Holding above this price would keep the bullish setup intact, while a decisive break below it would weaken the trade thesis. Traders should look for a reclaim, a successful retest, and stronger volume before treating $8.50 as confirmed support.
💰 What are the potential profit targets?
The planned profit targets are $9.00, $9.85, $10.50, $11.00, $11.50, $12.00, and $12.50. Taking profits in stages can help protect gains while leaving a smaller position available for a continued move higher.